Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-179811 for Clostridium difficile infection
2010-020941-29Phase 2Terminated
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cadazolid in Clostridioides difficile colitis (CDI) (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoint: Clinical cure. Started Oct 2010; status: terminated.
02
Drugs
cadazolid
03
Conditions
Clostridioides difficile colitis (CDI)
Beyond the preview
Go deeper on 2010-020941-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020941-29.